© Reuters. FILE PHOTO: A vial containing the Moderna COVID-19 vaccine is seen at a temporary vaccination center of Swiss Medix health center as the spread of the coronavirus disease continues, in the Offene St. Jakob Kirche Reformed church in Zurich, Switzerland May
SEOUL (Reuters) – Shares in South Korean drug contract manufacturer Samsung (KS:) BioLogics rose as much as 5.2% in early Monday trade, after it agreed to fill-finish manufacture Moderna (NASDAQ:)’s COVID-19 vaccine.
The agreement was part of Moderna Inc and Novavax (NASDAQ:) Inc entering into a deal with the South Korean government to manufacture their COVID-19 vaccines.
The wider market was down 0.2% as of 0007 GMT.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.